December 20, 2021

Minaris Regenerative Medicine Appoints Hiroto Bando as New General Manager

Chief Operating Officer Appointed for Minaris’ Operations in Japan

ALLENDALE, NJ., USA, and YOKOHAMA, JAPAN – Dec. 20, 2021—Minaris Regenerative Medicine is pleased to announce new appointments to strengthen its global and regional leadership.

Hiroto Bando, PhD, who joined Minaris Regenerative Medicine as Deputy General Manager, Regenerative Medicine Business Sector (RMBS), Showa Denko Materials Co., Ltd., in November 2020, will become General Manager, RMBS as well as President and Chief Executive Officer of Minaris Regenerative Medicine, LLC in the United States, effective January 4, 2022. He remains President and Chief Executive Officer of Minaris Regenerative Medicine Co., Ltd., Japan.

In Japan, Takuya Muramoto, PhD, will join Minaris Regenerative Medicine Co., Ltd. in the role of Chief Operating Officer, effective January 1, 2022. He joins the company with more than fifteen years’ experience in the pharmaceutical industry, including five years in cell manufacturing leadership roles at Takeda Pharmaceutical Company Ltd.

Kazuchika Furuishi, PhD, will leave his roles as General Manager, RMBS, Showa Denko Materials Co. Ltd., and President and CEO, Minaris Regenerative Medicine, LLC in the United States, effective January 4, 2022. He will continue to support the business, ensuring a smooth transition, through March 2022. He joined Showa Denko Materials Co., Ltd. for the main purpose of establishing the foundation of a Life Science business strategy through the acquisition of Minaris Regenerative Medicine, LLC (ex “PCT”). He strengthened the business’ competitiveness with global expansion including the acquisition of Minaris Regenerative Medicine GmbH (ex “apceth Biopharma”). He was instrumental in founding the RMBS Yokohama site (current Minaris Regenerative Medicine Co., Ltd.).  

“Congratulations to Hiroto for his appointment as General Manager, RMBS, and CEO of Minaris in the United States and welcome to Takuya to his role as COO of Minaris in Japan. I am pleased to see effective promotion and strengthening for these global and regional roles and have confidence in a successful leadership transition as Minaris Regenerative Medicine continues to deliver on its mission of creating cell therapy miracles together,” said Noriaki Kawata, Corporate Officer, General Manager, Life Science Business Headquarters, Showa Denko Materials Co., Ltd. “We thank Kazuchika for his great leadership to the company over the past years.”

About Minaris Regenerative Medicine 

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in the North America, Europe, and Asia allow us to supply patients worldwide with life-changing therapies.  Minaris Regenerative Medicine is wholly owned by Showa Denko Materials Co., Ltd.

For more information, please visit www.rm.minaris.com

Hiroto Bando, PhD, Profile

Hiroto_Headshot

Hiroto joined Minaris Regenerative Medicine in November 2020 with over 20 years’ experience in the pharmaceutical industry. Hiroto is the Deputy General Manager of the RMBS of Showa Denko Materials Co., Ltd. and President and Chief Executive Officer of Minaris Regenerative Medicine Co., Ltd. His responsibilities include coordinating global Business Development activities and developing business strategies that provide global leadership and oversight. Hiroto received his PhD in pharmaceutical science from Kyoto University, performed post-doctoral work at the College of Pharmacy at the University of Texas and holds an MBA from Kenichi Ohmae Graduate School of Business.

 Takuya Muramoto, PhD, Profile

With over 15 years’ experience in the pharmaceutical industry, Takuya has been appointed Chief Operating Officer of Minaris Regenerative Medicine Co., Ltd. Takuya has served most recently at Takeda Pharmaceutical Company Ltd. as group manager for technical project management and manufacturing in the cell therapies translational engine, and prior to that as director for cell manufacturing strategy. He has previously served in other leadership, research, process development and technical sales roles in both the regenerative medicine and biologics fields. Takuya received his PhD and Master’s Degree in Biosciences from Nara Institute of Science and Technology, and his Bachelor’s Degree in Agriculture from Iwate University. 

For more information, contact:

Luc St-Onge, Ph.D.

Global Head of Sales and Marketing

Minaris Regenerative Medicine GmbH

E-Mail: press@rm.minaris.de

Phone: +49 (0)89 700 9608-0

Media Contact Info:

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Soltuions (HCATS, formerly PCT or PCT Cell Therapy Services), apceth Biopharma GmBH are all now operating under the name Minaris Regenerative Medicine. Hitachi Chemical Co., Ltd. has been renamed Showa Denko Materials Co., Ltd.

Stay up to date
on the latest news